Selvita ($250m market cap) is an oncology focused biotechnology company. Broad oncology targeted therapeutics pipeline includes kinase inhibitor and synthetic lethality programs. Lead programs include SEL24, a first in class PIM/FLT3 kinase inhibitor in Ph 1/2 in AML (partnered with Menarini) and SEL120, a small molecule selective CDK8 inhibitor for leukemias, lymphomas, and solid tumors, which received FDA IND acceptance in March 2019, and Ph 1/2 initiation expected in H1 2019. Earlier stage pipeline from Cancer Cell Metabolism and Immunometabolism Platform and Immuno-oncology Platform.
Phase l or ll, Pre-Clinical Stage
100MM - 500MM
Park Life Science
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.